Showing 1151-1160 of 9359 results for "".
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel Pharmaceuticals Limited. Independent Data Safety Monitoring Board stated…
- Merz Pharma Group Acquires Anteis S.A.https://practicaldermatology.com/news/20131112-merz_pharma_group_acquires_anteis_sa/2459418/Merz Pharma Group has entered into a definitive agreement to acquire Anteis S.A., a Swiss company that specializes in the development, manufacture, and commercialization of medical devices in the area of aesthetics. With products available in more than 90 countries on five continents, Anteis has be…
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for t…
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primaril…
- Medicis Announces Winners of First Annual I Acanya Succeed Scholarship Programhttps://practicaldermatology.com/news/20131007-medicis_announces_winners_of_first_annual_i_acanya_succeed_scholarship_program/2459442/Medics, a division of Valeant Pharmaceuticals North America LLC, recently announced the winners of its first I Acanya Succeed scholarship program, an education-based initiative that provides scholarships to college students who have taken an active role in managing their acne. Three winners, repres…
- Modernizing Medicine and Miraca Life Sciences Partner to Create Enhanced EMR and Pathology Lab Integrationhttps://practicaldermatology.com/news/20130926-modernizing_medicine_and_miraca_life_sciences_partner_to_create_enhanced_emr_and_pathology_lab_integration/2459448/Modernizing Medicine, which created the Electronic Medical Assistant (EMA), a cloud-based, specialty-specific electronic medical record (EMR) system, and Miraca Life Sciences (MLS), a specialist in the development and commercialization of subspecialty expert anatomic pathology…
- Alma® Lasers Kicks of Nationwide Roadshow, Practice Success Seminarshttps://practicaldermatology.com/news/20130917-alma_kicks_off_nationwide_roadshow/2459458/Alma® Lasers kicks off its Practice for Success series of seminars this week. Seminars, led by aesthetic professionals, will focus on marketing strategies proven to grow aesthetic practices. There are also opportunities for hands-on participation as industry experts demonstrate the latest Alma tec…
- Speedier Drug Approvals Not Tied to Increased Warnings or Health Riskshttps://practicaldermatology.com/news/20130815-speedier_drug_approvals_not_tied_to_increased_warnings_or_health_risks/2459478/Faster drug approvals in the US and Canada are not linked to increases in the number of serious drug safety warnings issued by regulators, nor to actual evidence of health risks, according to new research. Investigators compared data about the number of drug safety warnings issued by regulators in …
- Merz Acquires Neocutis' Skin Care Divisionhttps://practicaldermatology.com/news/20130801-merz_acquires_neocutis/2459486/Merz Pharma Group has acquired the cosmetics, over-the-counter, and prescription skin care businesses of Swiss dermatology company Neocutis. The company's North American division will integrate marketing of Neocutis' line of physician-dispensed topical skin care products in the US. “Neocutis' line…
- Viscot Releases Prep-Resistant Ink Markerhttps://practicaldermatology.com/news/20130611-viscot_releases_prep-resistant_ink_marker/2459516/AllSkin Plus+ with Prep Resistant Ink is the first prep-resistant ink marker that offers maximum visibility and prep resistance on all skin tones. Its VIXL brilliant blue ink provides enhanced visibility even after prep and other fluids and remains visible up to 10 times longer than traditional ink…